Doxorubicin (DOX)

DRUG2 trials

Sponsors

PharmaMar, Tanta University

Conditions

Breast CancerDoxorubicin Induced CardiomyopathySmall-cell Lung Cancer

Phase 1

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Not yet recruitingNCT07370506

Tanta UniversityBreast Cancer, Doxorubicin Induced Cardiomyopathy

Start: 2026-02-01End: 2027-02-01Target: 36Updated: 2026-01-29

Phase 3

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

CompletedNCT02566993

PharmaMarSmall-cell Lung Cancer

Start: 2016-08-30End: 2020-02-24Updated: 2021-10-28

Related Papers

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.

2024-02-134 citations

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.

Journal of Clinical Oncology2023-06-011 citations

Safety analysis of lurbinectedin versus topotecan in elderly patients.

Journal of Clinical Oncology2023-06-01

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

2022-10-1477 citations

Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.

Journal of Clinical Oncology2022-06-016 citations

ATLANTIS: A Phase III Study of Lurbinectedin/Doxorubicin Versus Topotecan or Cyclophosphamide/Doxorubicin/Vincristine in Patients with Small-Cell Lung Cancer Who Have Failed one Prior Platinum-Containing Line

Future Oncology2018-10-2682 citations

ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs<i>.</i> CAV or topotecan (T) in small-cell lung cancer after platinum therapy.

Journal of Clinical Oncology2018-05-204 citations